Grandfield & Dodd LLC bought a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 210,330 shares of the medical equipment provider's stock, valued at approximately $13,192,000.
Other large investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Smith & Nephew SNATS in the 2nd quarter worth $505,323,000. Bank of New York Mellon Corp purchased a new position in shares of Smith & Nephew SNATS in the second quarter valued at $89,325,000. Goldman Sachs Group Inc. grew its stake in shares of Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock valued at $50,255,000 after acquiring an additional 583,809 shares in the last quarter. Bank of America Corp DE grew its stake in Smith & Nephew SNATS by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider's stock valued at $35,828,000 after purchasing an additional 575,666 shares in the last quarter. Finally, Deutsche Bank AG bought a new stake in shares of Smith & Nephew SNATS in the second quarter worth $33,563,000. Hedge funds and other institutional investors own 25.64% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the company. Weiss Ratings lowered Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, June 11th. Sanford C. Bernstein set a $31.85 price objective on shares of Smith & Nephew SNATS in a report on Monday, May 11th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, Morgan Stanley restated an "overweight" rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $30.93.
Get Our Latest Report on SNN
Smith & Nephew SNATS Trading Down 0.4%
Shares of SNN stock opened at $29.69 on Tuesday. Smith & Nephew SNATS, Inc. has a 1-year low of $28.56 and a 1-year high of $38.79. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock's fifty day simple moving average is $30.44 and its 200-day simple moving average is $31.98.
Smith & Nephew SNATS Announces Dividend
The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.
About Smith & Nephew SNATS
(
Free Report)
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
